Obstructive hypertrophic cardiomyopathy (HCM) is most commonly caused by disorders of cardiac muscle proteins. How does targeted treatment for this disease work? We bring a concise, graphically processed overview of the efficacy and mechanism of action of the first selective cardiac myosin inhibitor.
Don‘t have an account? Create new account
Authors: doc. MUDr. David Zemánek, Ph.D., MUDr. Anna Chaloupka, Ph.D.
Enter the email address that you registered with. We will send you instructions on how to set a new password.
